SCHEMBL5048424

SCHEMBL5048424

CCCCCCC1CCN(c2ncnc(Nc3ccc(S(C)(=O)=O)cc3F)c2[N+](=O)[O-])CC1

nearest known ligand 0.62

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 20/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL386117 0.88 GPR119 (0.61) GPR119
SCHEMBL390754 0.80 GPR119 (0.79) GPR119
SCHEMBL389252 0.79 GPR119 (0.79) GPR119
SCHEMBL6223583 0.78 GPR119 (0.62) GPR119
SCHEMBL27834742 0.78 GPR119 (0.68) GPR119
SCHEMBL114213 0.77 GPR119 (1.00) GPR119
SCHEMBL5133954 0.77 GPR119 (0.76) GPR119
SCHEMBL6041149 0.77 GPR119 (0.65) GPR119
SCHEMBL3876652 0.76 GPR119 (0.68) GPR119
SCHEMBL6041137 0.76 GPR119 (0.62) GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004157-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO Arena Pharmaceuticals, Inc. (US) 2008-12-24 EP disclosed
WO-2007120702-A2 USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO ARENA PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed
EP-1599468-A1 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA Arena Pharmaceuticals, Inc. (US) 2005-11-30 EP disclosed
WO-2004065380-A1 1,2,3-TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PRPPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO SUCH AS DIABETES AND HYPERGLYCEMIA ARENA PHARMACEUTICALS INC. (US) 2004-08-05 WO disclosed